BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual MeetingAccesswire • 02/14/24
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-MarketGlobeNewsWire • 02/06/24
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc DiseaseGlobeNewsWire • 02/05/24
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual MeetingGlobeNewsWire • 02/01/24
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity ProgramGlobeNewsWire • 12/12/23
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CityGlobeNewsWire • 10/09/23
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”Accesswire • 09/18/23
BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsGlobeNewsWire • 09/12/23
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc DiseaseGlobeNewsWire • 09/08/23
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAccesswire • 08/30/23
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of SharesAccesswire • 08/02/23
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The DiscussionAccesswire • 07/31/23
Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)GuruFocus • 07/26/23
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York StateAccesswire • 07/21/23
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline OpportunitiesAccesswire • 07/07/23
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any ChangesGlobeNewsWire • 06/27/23
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETGlobeNewsWire • 06/16/23
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight ItAccesswire • 06/15/23
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc DiseaseGlobeNewsWire • 06/12/23
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare ConferenceGlobeNewsWire • 06/01/23
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell ProcessingGlobeNewsWire • 05/31/23
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® ProgramGlobeNewsWire • 05/15/23
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy MarketAccesswire • 05/12/23
